Name | Deterministic value | Range | Distribution | Source | |
Minimum | Maximum | ||||
Discount rates | |||||
Cost discount rate | 0.035 | Fixed | Pharmacoeconomic guidelines (NICE)17 | ||
Outcome discount rate | 0.035 | Fixed | Pharmacoeconomic guidelines (NICE)17 | ||
Costs* | |||||
Costs of TARGIT-IORT | 2069 | 1552 | 2586 | Triangular | Carl Zeiss, UK |
Costs of EBRT | 3092 | 2319 | 3865 | Triangular | HRG code SC29Z, NHS reference costs 2012–201333 |
Annual cost of being disease free | 1200 | 900 | 1200 | Triangular | HRG code JA09H, NHS reference costs 2012–201333 |
Annual cost of local recurrence | 4231 | 3173 | 5289 | Triangular | Mansel et al 19 |
Annual cost of distant recurrence | 5417 | 4063 | 6771 | Triangular | Mansel et al 19 |
Probabilities | |||||
Probability of disease free to local recurrence in TARGIT-IORT patients | 0.00424 | 0.00318 | 0.0053 | Triangular | Vaidya et al 7 |
Probability of disease free to local recurrence in EBRT patients | 0.00221 | 0.00166 | 0.00276 | Triangular | |
Probability of disease free to distant recurrence in TARGIT-IORT patients | 0.00984 | 0.00738 | 0.0123 | Triangular | Vaidya et al 7 |
Probability of disease free to distant recurrence in EBRT patients | 0.0096 | 0.0072 | 0.012 | Triangular | Vaidya et al 7 |
Probability of disease free to non-breast cancer death in TARGIT-IORT patients | 0.003 | 0.0025 | 0.00375 | Triangular | Vaidya et al 7 |
Probability of disease free to non-breast cancer death in EBRT patients | 0.009 | 0.00675 | 0.01125 | Triangular | Vaidya et al 7 |
Probability of breast cancer death in TARGIT-IORT patients | 0.00671 | 0.00503 | 0.00838 | Triangular | Vaidya et al 7 |
Probability of breast cancer death in EBRT patients | 0.0055 | 0.00412 | 0.00687 | Triangular | Vaidya et al 7 |
Probability of distant recurrence to breast cancer death in TARGIT-IORT patients | 0.682 | 0.511 | 0.853 | Triangular | Calculated |
Probability of distant recurrence to breast cancer death in EBRT patients | 0.569 | 0.426 | 0.710 | Triangular | Calculated |
Probability of local recurrence to disease free | 1 | Fixed | Expert opinion/model assumption | ||
Utilities | |||||
Utility value in disease-free patients | 0.989 | 0.742 | 1 | Triangular | Mansel et al 19 |
Utility value in local recurrence | 0.911 | 0.683 | 1 | Triangular | Mansel et al 19 |
Utility value in distant recurrence | 0.882 | 0.661 | 1 | Triangular | Mansel et al 19 |
*All costs are in 2014 British pound sterling.
EBRT, external-beam radiation therapy; HRG, Health Resource Group; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; TARGIT-IORT, targeted intraoperative radio therapy.